Full-Time

Vice President

Controller

Posted on 4/30/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops broad-spectrum bacterial infection vaccines

Biotechnology

Senior, Expert

San Carlos, CA, USA

Requirements
  • CPA and B.A. degree in Accounting, Finance or Business
  • 15+ years accounting experience, including at least five years in a public company
  • 5+ years of Big 4 audit experience required; biotech/life sciences and manufacturing experience
  • 7+ years’ experience leading people managers and providing mentoring, coaching, and development
  • Strong knowledge and understanding of US GAAP accounting principles and emerging technical guidance
  • Experience operating within a public company subject to a Sarbanes-Oxley control structures
  • Adept at managing external service providers
  • Excellent interpersonal and communication skills
  • Results Orientation
  • Change Leadership
  • Emotional maturity and ability to effectively facilitate change
  • Possesses a sense of urgency
  • Ability to deal with business issues collaboratively
  • Embodies Vaxcyte’s cultural attributes: caring, courage, excellence, and passion
Responsibilities
  • Lead key growth initiatives and buildout of finance operations and systems
  • Manage general accounting functions including monthly and quarterly close, accounts payable, payroll, and equity plan administration
  • Oversee reporting of internal and external financial statements, SEC filings, and annual proxy statements
  • Manage SOX 404 compliance program and internal control structure
  • Prepare materials for Board of Directors and Audit Committee meetings
  • Ensure integrity of financial systems and compliance with accounting policies
  • Manage relationship with external auditors and SOX internal auditors
  • Implement process improvements and system enhancements
  • Provide cross-functional support and mentor team members

Vaxcyte is centered on creating advanced vaccines such as VAX-24, a sophisticated 24-valent pneumococcal conjugate vaccine, by utilizing cutting-edge chemistry and the XpressCF™ cell-free protein synthesis platform. The company prioritizes developing high-fidelity, broad-spectrum vaccines to combat bacterial infections, continuously expanding its product pipeline with innovations like VAX-31 for various bacterial threats.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

San Carlos, California

Founded

2013

Growth & Insights
Headcount

6 month growth

33%

1 year growth

69%

2 year growth

165%